​​Sweeteners and glucose metabolism in health and type 2 diabetes​

Adelaide University blue graphic logo

​​Effects of Renally Excreted low-calorie Sweeteners On URinary gluCose Excretion and whole-body glucose homeostasis: A double-blind, randomised, placebo-controlled Trial in health and type 2 diabetes​.

About the study

​​Low-calorie sweeteners (LCS) have been widely used in food and beverages in recent decades. While several international diabetes management guidelines recommend the use of LCS to replace sugar to prevent and manage type 2 diabetes, a recent World Health Organisation (WHO) report highlighted that people who consume LCS regularly may have an increased risk of developing type 2 diabetes. The current study is designed to investigate whether consumption of renally excreted LCS affects the amount of glucose excreted in the urine and blood glucose control in healthy people and people with type 2 diabetes.

​In this study, we will specifically study the most widely used LCS, acesulfame potassium (Ace-K), which is absorbed from the gut and excreted in the urine. Results will be compared with another LCS, sucralose, which is poorly absorbed and is excreted mainly in the faeces, and a flavourless dietary fibre, cellulose.

​Eligible participants will be required to attend 2 sessions (before and after the intervention), 8am to 1pm approximately each, over 2 weeks period.​

Eligibility requirements

​​To be eligible for this study, you should be:

​Type 2 diabetes

  • ​Have type 2 diabetes
  • Managed by diet or <3 oral diabetes medications
  • ​NOT taking Dapagliflozin (Forxiga), Empagliflozin (Jardiance), or Ertugliflozin (Steglatro)
  • ​Aged 18 – 70 years
  • Bbody mass index (BMI) 20 -40 kg/m2

​​Or healthy

  • ​in generally good health
  • aged 18 – 70 years
  • body mass index (BMI) 18 -30 kg/m2

​Participants must be able to attend the Clinical Research Facility at the Adelaide Health and Medical Sciences Building on North Terrace.​

Recruitment timeline

​​Start of recruitment: January 2025
​End of recruitment: December 2027​

Benefits

​​After successfully completing the trial, an honorarium of up to $300 will paid via EFT transfer to participants for their time.​

Ethics Protocol No.

​​​2024HRE00269​​

Contact us

To find out more information about participating in this study please contact: Michelle Bound or Jacqui Grivell.

Telephone

Phone: +61 8 8313 6676

Email

Email: ​​diabetes@adelaide.edu.au